IgA nephropathy is a type of kidney disease that is typically treated with various medicines and lifestyle changes. Learn more about IgA nephropathy treatment here.

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the ...

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

New research suggests that people using next-generation weight loss drugs may be losing weight without the nutritional support needed to protect long-term health. People taking newer prescription weig ...

A longevity-linked metabolite restored key memory processes in Alzheimer’s models, highlighting aging biology as a promising therapeutic target. Singapore ranks among the countries with the longest ...

Slumber, a rapidly emerging leader in sleep wellness, today announced the launch of Night Lytestm, a magnesium-based sleep powder formulated to enhance relaxation, support overnight recovery, and ...

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

Scientists are testing the ancient herb borage to see which healing claims hold up and where modern evidence still falls ...

According to DelveInsight’s latest analysis, Nipocalimab is expected to capture meaningful market share across both prevalent ...

In the sophisticated world of endocrinology and molecular biology, few compounds have sparked as much curiosity as CJC-1295 DAC. As a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), this ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...